Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
Date:11/3/2009

P basis Onyx recorded net income of $21.7 million, or $0.37 per diluted share, compared with a net income of $32.1 million, or $0.57 per diluted share, for the same period in 2008.

Management Conference Call Today

Onyx will host a teleconference and webcast to provide a general business overview and discuss financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on November 3, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-619-6547 and using the passcode 25674242. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25674242 approximately one hour after the teleconference concludes. The replay will be available through December 3, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, is developing and marketing Nexavar(®) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit http://www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding sales trends and commercial activities, the timing, progress and results of clinical development
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... plastic surgeon, Dr. Michael Niccole says there are plenty of ways ... time to research and do the homework before jumping into a ... ... March 25, 2009 -- Adapting one,s priorities to today,s changed economy ...
... and LOS ANGELES, March 25 AmeriCares, a nonprofit ... than $1.4 million worth of lifesaving medicines and medical ... Darfur refugees in Chad. The medical aid will ... from serious injuries, infections, diarrhea and chronic diseases, in ...
... Ind., March 25 OBS Medical has entered ... of London-based insurer of medical malpractice for US ... a reduced cost to hospitals that implement OBS,s ... of clinical crises.Recognized by Frost and Sullivan as ...
... to weaknesses in the U.S. economy, plastic surgery ... to the newest national procedural statistics report from ... 2008, doctors performed over 12 million cosmetic plastic ... procedures. Surgical numbers dropped nine percent and minimally-invasive ...
... ULU) today announced that it has scheduled a ... 2008 financial results and provide a general business update on ... in the conference call please dial (800) 357-0498, for international ... minutes prior to the initiation of the teleconference. If ...
... official IRS determination letter. , ... New York, NY (Vocus) March 25, ... receipt of their official IRS determination letter. This letter confirms Angie,s Spa ... spa services for cancer patients undergoing chemotherapy. , , ,Thanks ...
Cached Medicine News:Health News:Orange County Plastic Surgeon Warns: When It Comes To The Face And Body, The Best Deal Could Cost More 2Health News:AmeriCares and International Medical Corps Partner to Bring Lifesaving Aid to Chad 2Health News:OBS Medical's Visensia Patient Monitoring Technology Lowers Cost of Medical Malpractice Insurance 2Health News:Recession cuts many, not all plastic surgery procedures 2Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update 2Health News:Angie's Spa Receives Official Acknowledgment of Non-Profit Status 2
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Jan. 10, 2011 Ascension Orthopedics, Inc., a market ... a European patent for a PyroCarbon humeral head design ... Modular Shoulder System released in September 2010. ... of Ascension Orthopedics, commented, "I am very pleased our ...
... Inc. (Nasdaq: RDEA ) today announced that ... Bayer HealthCare AG (Bayer) under the terms of their ... Ardea,s mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer ... initiation of a Phase 2 clinical study evaluating BAY ...
Cached Medicine Technology:Ascension Orthopedics Granted Patent for PyroCarbon Humeral Head Design 2Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration 2Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration 3
... Managing diabetes requires making decisions about insulin ... exercise. These decisions are guided by data ... information, and by the patterns that can ... Care Providers when the data is presented ...
... The Worlds First Solid-State Three-Color ... chosen to purchase over 3,000 Lumenis ... a busy practice, the Novus Varia ... lasers into a single, compact system ...
... Solid-State Three-Color Photocoagulator.,Retinal physicians throughout the ... 3,000 Lumenis multi-color photocoagulators.,For the retinal ... Novus Varia integrates green, yellow, and ... compact system that supports your treatment ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Medicine Products: